December 2024

MagnaPharm is proud to announce a new strategic partnership with Juvisé Pharmaceuticals, a trusted pharmaceutical company dedicated to prioritizing essential medicines and significantly enhancing care for patients with a wide range of conditions, including multiple sclerosis, gastroenterology, oncology, cardiology, and rheumatology.

This collaboration, initiated on November 4th, will make this treatment available to patients in selected CEE regions, providing a solution in managing this complex condition.

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. It is one of the most common causes of neurological disability in the young adult population. Worldwide about 2.8 million people are affected, with an increasing incidence and prevalence over the last decades.¹

Despite advances in research, there is currently no cure for MS.. Ponvory®(ponesimod) is a first-line treatment option in active forms of relapsing multiple sclerosis (RMS), which is the most common form of the disease (approximately 80% of patients), affecting particularly women around the age of 30-years-old. Ponvory® is the first oral Disease Modifying Treatment (DMT) to demonstrate superior efficacy compared to teriflunomide in a large head-to-head Phase III study (OPTIMUM) in adult patients with active RMS. Ponvory® demonstrated a 30.5% reduction in Annualized Relapse Rate (primary endpoint), as well as reduction in MRI activity and fatigue (secondary endpoints).²

The partnership between MagnaPharm and Juvisé Pharmaceuticals represents a significant step forward in the fight against MS and we are all fully committed to working alongside healthcare professionals with the aim of becoming trusted partners for them and for patients with multiple sclerosis.

“We are thrilled and proud to announce the further development of our strong and longstanding partnership with Juvisé Pharmaceuticals. This collaboration is a clear demonstration of MagnaPharms’s capabilities and unwavering commitment to delivering excellence across the CEE region. For over 30 years, we have focused on expanding access to innovative and effective medicines, and this partnership is yet another step forward in that journey. Our alliance with Juvisé Pharmaceuticals highlights our shared dedication to bringing advanced therapeutic solutions to patients with multiple sclerosis. Ponvory® represents a major advancement in care, and we are honoured to be working alongside Juvisé Pharmaceuticals to market this treatment in the CEE market.”

Karol Michalak, CEO MagnaPharm

” We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis. Confident that MagnaPharm is the ideal partner for this endeavor in CEE countries, we are entrusting them with Ponvory® distribution and accessibility to patients. This decision reaffirms our trust in MagnaPharm, built on the success of our partnership with Pylera in gastroenterology since 2023.”

Emilie Gounon, COO Juvisé Pharmaceuticals

About MagnaPharm

MagnaPharm is a premier pharmaceutical and consumer healthcare service provider in Central & Eastern Europe. MagnaPharm is the partner of choice on the Central and Eastern Europe pharmaceutical market, offering a unique and full range of services on the distribution, marketing, sales, pharmaceutical retail, market access, pricing and medical services segments. MagnaPharm is going an extra mile to fulfil the demands of its reputable partners, multinational and specialty international pharmaceutical companies that have decided not to operate directly in CEE or already operating in CEE but outsourcing parts of their portfolios. MagnaPharm operates in all main CEE countries: Romania, Bulgaria, Poland, Hungary, Czech Republic, Slovakia, Serbia, Slovenia, Lithuania, Estonia, Latvia, Croatia, Bosnia, Albania, Montenegro and North Macedonia. For more info about MagnaPharm, please visit: www.magnapharm.eu

References

¹ Jakimovski, D. ∙ Bittner, S. ∙ Zivadinov, R. ∙ et al. Multiple sclerosis Lancet. 2024; 403:183-202

² Kappos, Ludwig et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial JAMA neurology vol. 78,5 (2021): 558-567. doi:10.1001/jamaneurol.2021.0405